CD19 and B-cell chronic lymphocytic leukemia: Regarding the observed increase of CD19- cells in CLL samples upon OBI (and to a lesser extent RTX) treatment, we speculate that OBI might induce a down-regulation of CD19 as has been previously described for RTX (57, 58).